Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk
Authors:
Open Access
- 23 June 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 28611
Abstract
EGFR is a potential therapeutic target for treating bladder cancer, but has not been approved for clinical use yet. Metformin is a widely used antidiabetic drug and has demonstrated interesting anticancer effects on various cancer models, alone or in combination with chemotherapeutic drugs. The efficacy of gefitinib, a well-known EGFR tyrosine kinase inhibitor, combined with metformin was assessed on bladder cancer and underlying mechanisms were explored. This drug combination induced a strong anti-proliferative and anti-colony forming effect and apoptosis in bladder cancer cell lines. Gefitinib suppressed EGFR signaling and inhibited phosphorylation of ERK and Akt. Metformin amplified this inhibitory effect and enhanced gefitinib-induced activation of AMPK signaling pathway. In vivo intravesical treatment of metformin and gefitinib on syngeneic orthotopic mice confirmed the significant inhibitory effect on bladder tumor growth. These two drugs may be an excellent combination for the treatment of bladder cancer through intravesical instillation.Keywords
This publication has 30 references indexed in Scilit:
- Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer CellsPLOS ONE, 2014
- The granulocyte macrophage–colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancerStem Cell Research, 2014
- Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder CancerClinical Cancer Research, 2013
- Investigating Metformin for Cancer Prevention and Treatment: The End of the BeginningCancer Discovery, 2012
- A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder CancerMolecular Medicine, 2011
- The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder CancerEuropean Urology, 2010
- Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urotheliumBJU International, 2010
- Novel approaches with targeted therapies in bladder cancerCritical Reviews in Oncology/Hematology, 2003
- Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth.2002
- The epidermal growth factor receptor and the prognosis of bladder cancerCancer, 1990